INS and metabolic dysfunction-associated steatohepatitis: The mechanism of ipragliflozin in the treatment of NASH is mainly considered to be an insulin-independent glucose-lowering effect with subsequent caloric loss via the inhibition of glucose reabsorption in the renal proximal tubules [25–27].